Your session is about to expire
← Back to Search
Intervention for Wound Bleeding
Phase < 1
Waitlist Available
Led By Nicholas Golda, MD
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* All adult (18 years or older) patients presenting for Mohs micrographic surgery (MMS) for the treatment of melanoma or nonmelanoma skin cancer (NMSC) with a wound that will be healing by granulation
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up three days
Awards & highlights
Summary
Bleeding after Mohs micrographic surgery for skin cancer is a low risk complication that can occur. This study aims to determine the effect of a drug, often used to reduce bleeding, called tranexamic acid when applied topically to the skin wound after surgery.
Eligible Conditions
- Wound Bleeding
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ three days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Rate of clinic evaluations of postoperative hemorrhagic complications
Rate of postoperative hemorrhagic complications
Rate of treatment interventions for postoperative hemorrhagic complications
Secondary outcome measures
Types of postoperative hemorrhagic complications
Side effects data
From 2012 Phase 4 trial • 100 Patients • NCT0074011622%
Readmissions
14%
Postoperative infections
10%
Re-operations
4%
Thromboembolic events
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo Group
Tranexamic Group
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: InterventionExperimental Treatment1 Intervention
Topical application of tranexamic acid to granulating wound defect status post Mohs micrographic surgery.
Group II: PlaceboPlacebo Group1 Intervention
Topical application of normal saline to granulating wound defect status post Mohs micrographic surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tranexamic acid
FDA approved
Find a Location
Who is running the clinical trial?
University of Missouri-ColumbiaLead Sponsor
376 Previous Clinical Trials
628,599 Total Patients Enrolled
Nicholas Golda, MDPrincipal InvestigatorUniversity of Missouri-Columbia
1 Previous Clinical Trials
160 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger